May 24, 2022
A COVID treatment for vulnerable Americans isn’t getting to them
Play • 28 min

It’s been roughly six months since AstraZeneca released a COVID-19 antibody treatment called Evusheld, designed for immunocompromised people. But a lack of outreach and unequal distribution has led to a complicated and confusing rollout — leaving millions of vulnerable Americans without protection. Plus, what experts look for in the minutes from Federal Reserve meetings and how high energy prices please investors but burden the economy.

More episodes
Clear search
Close search
Google apps
Main menu